Varicella-zoster virus.
PDF (438K)
Journal: 1996/December - Clinical Microbiology Reviews
ISSN: 0893-8512
PUBMED: 8809466
Abstract:
Varicella-zoster virus (VZV) is a ubiquitous human alphaherpesvirus that causes varicella (chicken pox) and herpes zoster (shingles). Varicella is a common childhood illness, characterized by fever, viremia, and scattered vesicular lesions of the skin. As is characteristic of the alphaherpesviruses, VZV establishes latency in cells of the dorsal root ganglia. Herpes zoster, caused by VZV reactivation, is a localized, painful, vesicular rash involving one or adjacent dermatomes. The incidence of herpes zoster increases with age or immunosuppression. The VZV virion consists of a nucleocapsid surrounding a core that contains the linear, double-stranded DNA genome; a protein tegument separates the capsid from the lipid envelope, which incorporates the major viral glycoproteins. VZV is found in a worldwide geographic distribution but is more prevalent in temperate climates. Primary VZV infection elicits immunoglobulin G (IgG), IgM, and IgA antibodies, which bind to many classes of viral proteins. Virus-specific cellular immunity is critical for controlling viral replication in healthy and immunocompromised patients with primary or recurrent VZV infections. Rapid laboratory confirmation of the diagnosis of varicella or herpes zoster, which can be accomplished by detecting viral proteins or DNA, is important to determine the need for antiviral therapy. Acyclovir is licensed for treatment of varicella and herpes zoster, and acyclovir, valacyclovir, and famciclovir are approved for herpes zoster. Passive antibody prophylaxis with varicella-zoster immune globulin is indicated for susceptible high-risk patients exposed to varicella. A live attenuated varicella vaccine (Oka/Merck strain) is now recommended for routine childhood immunization.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(116)
References
(247)
Diseases
(2)
Drugs
(3)
Chemicals
(2)
Organisms
(2)
Processes
(2)
Affiliates
(2)
Similar articles
Articles by the same authors
Discussion board
Clin Microbiol Rev 9(3): 361-381
PMID: 8809466

Varicella-zoster virus.

Abstract

Varicella-zoster virus (VZV) is a ubiquitous human alphaherpesvirus that causes varicella (chicken pox) and herpes zoster (shingles). Varicella is a common childhood illness, characterized by fever, viremia, and scattered vesicular lesions of the skin. As is characteristic of the alphaherpesviruses, VZV establishes latency in cells of the dorsal root ganglia. Herpes zoster, caused by VZV reactivation, is a localized, painful, vesicular rash involving one or adjacent dermatomes. The incidence of herpes zoster increases with age or immunosuppression. The VZV virion consists of a nucleocapsid surrounding a core that contains the linear, double-stranded DNA genome; a protein tegument separates the capsid from the lipid envelope, which incorporates the major viral glycoproteins. VZV is found in a worldwide geographic distribution but is more prevalent in temperate climates. Primary VZV infection elicits immunoglobulin G (IgG), IgM, and IgA antibodies, which bind to many classes of viral proteins. Virus-specific cellular immunity is critical for controlling viral replication in healthy and immunocompromised patients with primary or recurrent VZV infections. Rapid laboratory confirmation of the diagnosis of varicella or herpes zoster, which can be accomplished by detecting viral proteins or DNA, is important to determine the need for antiviral therapy. Acyclovir is licensed for treatment of varicella and herpes zoster, and acyclovir, valacyclovir, and famciclovir are approved for herpes zoster. Passive antibody prophylaxis with varicella-zoster immune globulin is indicated for susceptible high-risk patients exposed to varicella. A live attenuated varicella vaccine (Oka/Merck strain) is now recommended for routine childhood immunization.

Full Text

The Full Text of this article is available as a PDF (438K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Alessi E, Cusini M, Zerboni R, Cavicchini S, Uberti-Foppa C, Galli M, Moroni M. Unusual varicella zoster virus infection in patients with the acquired immunodeficiency syndrome. Arch Dermatol. 1988 Jul;124(7):1011–1013. [PubMed] [Google Scholar]
  • Amlie-Lefond C, Kleinschmidt-DeMasters BK, Mahalingam R, Davis LE, Gilden DH. The vasculopathy of varicella-zoster virus encephalitis. Ann Neurol. 1995 Jun;37(6):784–790. [PubMed] [Google Scholar]
  • Anderson DR, Schwartz J, Hunter NJ, Cottrill C, Bisaccia E, Klainer AS. Varicella hepatitis: a fatal case in a previously healthy, immunocompetent adult. Report of a case, autopsy, and review of the literature. Arch Intern Med. 1994 Sep 26;154(18):2101–2106. [PubMed] [Google Scholar]
  • Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics. 1986 Oct;78(4 Pt 2):748–756. [PubMed] [Google Scholar]
  • Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis. 1992 Aug;166 (Suppl 1):S35–S41. [PubMed] [Google Scholar]
  • Arvin AM, Kinney-Thomas E, Shriver K, Grose C, Koropchak CM, Scranton E, Wittek AE, Diaz PS. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol. 1986 Aug 15;137(4):1346–1351. [PubMed] [Google Scholar]
  • Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK. Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis. 1986 Sep;154(3):422–429. [PubMed] [Google Scholar]
  • Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis. 1983 Aug;148(2):200–205. [PubMed] [Google Scholar]
  • Arvin AM, Kushner JH, Feldman S, Baehner RL, Hammond D, Merigan TC. Human leukocyte interferon for the treatment of varicella in children with cancer. N Engl J Med. 1982 Apr 1;306(13):761–765. [PubMed] [Google Scholar]
  • Arvin AM, Sharp M, Smith S, Koropchak CM, Diaz PS, Kinchington P, Ruyechan W, Hay J. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol. 1991 Jan 1;146(1):257–264. [PubMed] [Google Scholar]
  • Asano Y, Itakura N, Hiroishi Y, Hirose S, Nagai T, Ozaki T, Yazaki T, Yamanishi K, Takahashi M. Viremia is present in incubation period in nonimmunocompromised children with varicella. J Pediatr. 1985 Jan;106(1):69–71. [PubMed] [Google Scholar]
  • Asano Y, Itakura N, Hiroishi Y, Hirose S, Ozaki T, Kuno K, Nagai T, Yazaki T, Yamanishi K, Takahashi M. Viral replication and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine recipients. J Infect Dis. 1985 Nov;152(5):863–868. [PubMed] [Google Scholar]
  • Asano Y, Itakura N, Kajita Y, Suga S, Yoshikawa T, Yazaki T, Ozaki T, Yamanishi K, Takahashi M. Severity of viremia and clinical findings in children with varicella. J Infect Dis. 1990 Jun;161(6):1095–1098. [PubMed] [Google Scholar]
  • Asano Y, Nakayama H, Yazaki T, Kato R, Hirose S. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics. 1977 Jan;59(1):3–7. [PubMed] [Google Scholar]
  • Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, Tsuzuki K, Ito S. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics. 1994 Oct;94(4 Pt 1):524–526. [PubMed] [Google Scholar]
  • Balducci J, Rodis JF, Rosengren S, Vintzileos AM, Spivey G, Vosseller C. Pregnancy outcome following first-trimester varicella infection. Obstet Gynecol. 1992 Jan;79(1):5–6. [PubMed] [Google Scholar]
  • Balfour HH., Jr Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management. Am J Med. 1988 Aug 29;85(2A):68–73. [PubMed] [Google Scholar]
  • Balfour HH, Jr, Benson C, Braun J, Cassens B, Erice A, Friedman-Kien A, Klein T, Polsky B, Safrin S. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr. 1994 Mar;7(3):254–260. [PubMed] [Google Scholar]
  • Balfour HH, Jr, Rotbart HA, Feldman S, Dunkle LM, Feder HM, Jr, Prober CG, Hayden GF, Steinberg S, Whitley RJ, Goldberg L, et al. Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group. J Pediatr. 1992 Apr;120(4 Pt 1):627–633. [PubMed] [Google Scholar]
  • Barnes DW, Whitley RJ. CNS diseases associated with varicella zoster virus and herpes simplex virus infection. Pathogenesis and current therapy. Neurol Clin. 1986 Feb;4(1):265–283. [PubMed] [Google Scholar]
  • Bennett GJ. Hypotheses on the pathogenesis of herpes zoster-associated pain. Ann Neurol. 1994;35 (Suppl):S38–S41. [PubMed] [Google Scholar]
  • Bergen RE, Sharp M, Sanchez A, Judd AK, Arvin AM. Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus. Viral Immunol. 1991 Fall;4(3):151–166. [PubMed] [Google Scholar]
  • Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun. 1981 Apr;32(1):24–27.[PMC free article] [PubMed] [Google Scholar]
  • Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995 Jul;39(7):1546–1553.[PMC free article] [PubMed] [Google Scholar]
  • Biron KK, Elion GB. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother. 1980 Sep;18(3):443–447.[PMC free article] [PubMed] [Google Scholar]
  • Bogger-Goren S, Baba K, Hurley P, Yabuuchi H, Takahashi M, Ogra PL. Antibody response to varicella-zoster virus after natural or vaccine-induced infection. J Infect Dis. 1982 Aug;146(2):260–265. [PubMed] [Google Scholar]
  • Bogger-Goren S, Bernstein JM, Gershon AA, Ogra PL. Mucosal cell-mediated immunity to varicella zoster virus: role in protection against disease. J Pediatr. 1984 Aug;105(2):195–199. [PubMed] [Google Scholar]
  • Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH., Jr Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis. 1994 Jul;170(1):68–75. [PubMed] [Google Scholar]
  • Brinker JP, Doern GV. Comparison of MRC-5 and A-549 cells in conventional culture tubes and shell vial assays for the detection of varicella-zoster virus. Diagn Microbiol Infect Dis. 1993 Jul;17(1):75–77. [PubMed] [Google Scholar]
  • Brunell PA. Transmission of chickenpox in a school setting prior to the observed exanthem. Am J Dis Child. 1989 Dec;143(12):1451–1452. [PubMed] [Google Scholar]
  • Brunell PA. Varicella in pregnancy, the fetus, and the newborn: problems in management. J Infect Dis. 1992 Aug;166 (Suppl 1):S42–S47. [PubMed] [Google Scholar]
  • Brunell PA, Gershon AA, Uduman SA, Steinberg S. Varicella-Zoster Immunoglobulins during Varicella, Latency, and Zoster. J Infect Dis. 1975 Jul;132(1):49–54. [PubMed] [Google Scholar]
  • Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM, Underwood R, Holmberg SD. Herpes zoster and human immunodeficiency virus infection. J Infect Dis. 1992 Nov;166(5):1153–1156. [PubMed] [Google Scholar]
  • Cohen JI, Seidel KE. Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7376–7380.[PMC free article] [PubMed] [Google Scholar]
  • Cohen JI, Seidel K. Varicella-zoster virus (VZV) open reading frame 10 protein, the homolog of the essential herpes simplex virus protein VP16, is dispensable for VZV replication in vitro. J Virol. 1994 Dec;68(12):7850–7858.[PMC free article] [PubMed] [Google Scholar]
  • Cohen PR, Grossman ME. Clinical features of human immunodeficiency virus-associated disseminated herpes zoster virus infection--a review of the literature. Clin Exp Dermatol. 1989 Jul;14(4):273–276. [PubMed] [Google Scholar]
  • Cohrs R, Mahalingam R, Dueland AN, Wolf W, Wellish M, Gilden DH. Restricted transcription of varicella-zoster virus in latently infected human trigeminal and thoracic ganglia. J Infect Dis. 1992 Aug;166 (Suppl 1):S24–S29. [PubMed] [Google Scholar]
  • Cohrs RJ, Barbour MB, Mahalingam R, Wellish M, Gilden DH. Varicella-zoster virus (VZV) transcription during latency in human ganglia: prevalence of VZV gene 21 transcripts in latently infected human ganglia. J Virol. 1995 Apr;69(4):2674–2678.[PMC free article] [PubMed] [Google Scholar]
  • Cohrs RJ, Srock K, Barbour MB, Owens G, Mahalingam R, Devlin ME, Wellish M, Gilden DH. Varicella-zoster virus (VZV) transcription during latency in human ganglia: construction of a cDNA library from latently infected human trigeminal ganglia and detection of a VZV transcript. J Virol. 1994 Dec;68(12):7900–7908.[PMC free article] [PubMed] [Google Scholar]
  • Colebunders R, Mann JM, Francis H, Bila K, Izaley L, Ilwaya M, Kakonde N, Quinn TC, Curran JW, Piot P. Herpes zoster in African patients: a clinical predictor of human immunodeficiency virus infection. J Infect Dis. 1988 Feb;157(2):314–318. [PubMed] [Google Scholar]
  • Connelly BL, Stanberry LR, Bernstein DI. Detection of varicella-zoster virus DNA in nasopharyngeal secretions of immune household contacts of varicella. J Infect Dis. 1993 Nov;168(5):1253–1255. [PubMed] [Google Scholar]
  • Cowan MR, Primm PA, Scott SM, Abramo TJ, Wiebe RA. Serious group A beta-hemolytic streptococcal infections complicating varicella. Ann Emerg Med. 1994 Apr;23(4):818–822. [PubMed] [Google Scholar]
  • Croen KD, Ostrove JM, Dragovic LJ, Straus SE. Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9773–9777.[PMC free article] [PubMed] [Google Scholar]
  • Cuthbertson G, Grose C. Biotinylated and radioactive DNA probes for detection of varicella-zoster virus genome in infected human cells. Mol Cell Probes. 1988 Sep;2(3):197–207. [PubMed] [Google Scholar]
  • Davison AJ, Edson CM, Ellis RW, Forghani B, Gilden D, Grose C, Keller PM, Vafai A, Wroblewska Z, Yamanishi K. New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products. J Virol. 1986 Mar;57(3):1195–1197.[PMC free article] [PubMed] [Google Scholar]
  • Davison AJ, Scott JE. The complete DNA sequence of varicella-zoster virus. J Gen Virol. 1986 Sep;67(Pt 9):1759–1816. [PubMed] [Google Scholar]
  • Debrus S, Sadzot-Delvaux C, Nikkels AF, Piette J, Rentier B. Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency. J Virol. 1995 May;69(5):3240–3245.[PMC free article] [PubMed] [Google Scholar]
  • Devlin ME, Gilden DH, Mahalingam R, Dueland AN, Cohrs R. Peripheral blood mononuclear cells of the elderly contain varicella-zoster virus DNA. J Infect Dis. 1992 Apr;165(4):619–622. [PubMed] [Google Scholar]
  • Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S, Arvin AM. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics. 1991 Feb;87(2):166–170. [PubMed] [Google Scholar]
  • Dolin R, Reichman RC, Mazur MH, Whitley RJ. NIH conference. Herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med. 1978 Sep;89(3):375–388. [PubMed] [Google Scholar]
  • Drew WL, Mintz L. Rapid diagnosis of varicella-zoster virus infection by direct immunofluorescence. Am J Clin Pathol. 1980 May;73(5):699–701. [PubMed] [Google Scholar]
  • Dueland AN, Devlin M, Martin JR, Mahalingam R, Cohrs R, Manz H, Trombley I, Gilden D. Fatal varicella-zoster virus meningoradiculitis without skin involvement. Ann Neurol. 1991 May;29(5):569–572. [PubMed] [Google Scholar]
  • Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM, Jr, Feldman S, Gershon AA, Levy ML, Hayden GF, McGuirt PV, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med. 1991 Nov 28;325(22):1539–1544. [PubMed] [Google Scholar]
  • Dworsky M, Whitley R, Alford C. Herpes zoster in early infancy. Am J Dis Child. 1980 Jun;134(6):618–619. [PubMed] [Google Scholar]
  • Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 1992 Dec;36(12):2747–2757.[PMC free article] [PubMed] [Google Scholar]
  • Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet. 1994 Jun 18;343(8912):1548–1551. [PubMed] [Google Scholar]
  • Englund JA, Arvin AM, Balfour HH., Jr Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children. J Clin Microbiol. 1990 Oct;28(10):2327–2330.[PMC free article] [PubMed] [Google Scholar]
  • Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH., Jr Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. J Pediatr. 1989 Jan;114(1):37–44. [PubMed] [Google Scholar]
  • Esiri MM, Tomlinson AH. Herpes Zoster. Demonstration of virus in trigeminal nerve and ganglion by immunofluorescence and electron microscopy. J Neurol Sci. 1972;15(1):35–48. [PubMed] [Google Scholar]
  • Esmann V, Geil JP, Kroon S, Fogh H, Peterslund NA, Petersen CS, Ronne-Rasmussen JO, Danielsen L. Prednisolone does not prevent post-herpetic neuralgia. Lancet. 1987 Jul 18;2(8551):126–129. [PubMed] [Google Scholar]
  • Feldhoff CM, Balfour HH, Jr, Simmons RL, Najarian JS, Mauer SM. Varicella in children with renal transplants. J Pediatr. 1981 Jan;98(1):25–31. [PubMed] [Google Scholar]
  • Feldman S, Hughes WT, Kim HY. Herpes zoster in children with cancer. Am J Dis Child. 1973 Aug;126(2):178–184. [PubMed] [Google Scholar]
  • Feldman S, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics. 1987 Oct;80(4):465–472. [PubMed] [Google Scholar]
  • Feldman SR, Ford MJ, Briggaman RA. Herpes zoster and facial palsy. Cutis. 1988 Dec;42(6):523–524. [PubMed] [Google Scholar]
  • Feusner JH, Slichter SJ, Harker LA. Mechanisms of thrombocytopenia in varicella. Am J Hematol. 1979;7(3):255–264. [PubMed] [Google Scholar]
  • Fleisher G, Henry W, McSorley M, Arbeter A, Plotkin S. Life-threatening complications of varicella. Am J Dis Child. 1981 Oct;135(10):896–899. [PubMed] [Google Scholar]
  • Forghani B, Ni L, Grose C. Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex. Virology. 1994 Mar;199(2):458–462. [PubMed] [Google Scholar]
  • Forghani B, Yu GJ, Hurst JW. Comparison of biotinylated DNA and RNA probes for rapid detection of varicella-zoster virus genome by in situ hybridization. J Clin Microbiol. 1991 Mar;29(3):583–591.[PMC free article] [PubMed] [Google Scholar]
  • Friedman SM, Margo CE, Connelly BL. Varicella-zoster virus retinitis as the initial manifestation of the acquired immunodeficiency syndrome. Am J Ophthalmol. 1994 Apr 15;117(4):536–538. [PubMed] [Google Scholar]
  • Furuta Y, Takasu T, Fukuda S, Sato-Matsumura KC, Inuyama Y, Hondo R, Nagashima K. Detection of varicella-zoster virus DNA in human geniculate ganglia by polymerase chain reaction. J Infect Dis. 1992 Nov;166(5):1157–1159. [PubMed] [Google Scholar]
  • Gershon AA. Human immune responses to live attenuated varicella vaccine. Rev Infect Dis. 1991 Nov-Dec;13 (Suppl 11):S957–S959. [PubMed] [Google Scholar]
  • Gershon AA. Varicella-zoster virus: prospects for control. Adv Pediatr Infect Dis. 1995;10:93–124. [PubMed] [Google Scholar]
  • Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S. Varicella vaccine: the American experience. J Infect Dis. 1992 Aug;166 (Suppl 1):S63–S68. [PubMed] [Google Scholar]
  • Gershon AA, Sherman DL, Zhu Z, Gabel CA, Ambron RT, Gershon MD. Intracellular transport of newly synthesized varicella-zoster virus: final envelopment in the trans-Golgi network. J Virol. 1994 Oct;68(10):6372–6390.[PMC free article] [PubMed] [Google Scholar]
  • Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin. A further assessment. N Engl J Med. 1974 Jan 31;290(5):243–245. [PubMed] [Google Scholar]
  • Gershon A, Steinberg S, Greenberg S, Taber L. Varicella-zoster-associated encephalitis: detection of specific antibody in cerebrospinal fluid. J Clin Microbiol. 1980 Dec;12(6):764–767.[PMC free article] [PubMed] [Google Scholar]
  • Gershon AA, Steinberg S, Silber R. Varicella-zoster viremia. J Pediatr. 1978 Jun;92(6):1033–1034. [PubMed] [Google Scholar]
  • Gershon AA, Steinberg SP. Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections. Infect Immun. 1979 Jul;25(1):170–174.[PMC free article] [PubMed] [Google Scholar]
  • Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med. 1989 Apr 6;320(14):892–897. [PubMed] [Google Scholar]
  • Gershon AA, Steinberg SP. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Infect Dis. 1990 Apr;161(4):661–666. [PubMed] [Google Scholar]
  • Gershon AA, Steinberg SP, Gelb L. Clinical reinfection with varicella-zoster virus. J Infect Dis. 1984 Feb;149(2):137–142. [PubMed] [Google Scholar]
  • Gershon AA, Steinberg SP, Gelb L, Galasso G, Borkowsky W, LaRussa P, Farrara A. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA. 1984 Jul 20;252(3):355–362. [PubMed] [Google Scholar]
  • Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis. 1988 Jul;158(1):132–137. [PubMed] [Google Scholar]
  • Ghatak NR, Zimmerman HM. Spinal ganglion in herpes zoster. A light and electron microscopic study. Arch Pathol. 1973 Jun;95(6):411–415. [PubMed] [Google Scholar]
  • Gilchrest B, Baden HP. Photodistribution of viral exanthems. Pediatrics. 1974 Aug;54(2):136–138. [PubMed] [Google Scholar]
  • Gilden DH, Beinlich BR, Rubinstien EM, Stommel E, Swenson R, Rubinstein D, Mahalingam R. Varicella-zoster virus myelitis: an expanding spectrum. Neurology. 1994 Oct;44(10):1818–1823. [PubMed] [Google Scholar]
  • Gilden DH, Dueland AN, Devlin ME, Mahalingam R, Cohrs R. Varicella-zoster virus reactivation without rash. J Infect Dis. 1992 Aug;166 (Suppl 1):S30–S34. [PubMed] [Google Scholar]
  • Gilden DH, Mahalingam R, Dueland AN, Cohrs R. Herpes zoster: pathogenesis and latency. Prog Med Virol. 1992;39:19–75. [PubMed] [Google Scholar]
  • Gilden DH, Wright RR, Schneck SA, Gwaltney JM, Jr, Mahalingam R. Zoster sine herpete, a clinical variant. Ann Neurol. 1994 May;35(5):530–533. [PubMed] [Google Scholar]
  • Giller RH, Winistorfer S, Grose C. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J Infect Dis. 1989 Dec;160(6):919–928. [PubMed] [Google Scholar]
  • Gleaves CA, Lee CF, Bustamante CI, Meyers JD. Use of murine monoclonal antibodies for laboratory diagnosis of varicella-zoster virus infection. J Clin Microbiol. 1988 Sep;26(9):1623–1625.[PMC free article] [PubMed] [Google Scholar]
  • Gnann JW., Jr New antivirals with activity against varicella-zoster virus. Ann Neurol. 1994;35 (Suppl):S69–S72. [PubMed] [Google Scholar]
  • Gogos CA, Bassaris HP, Vagenakis AG. Varicella pneumonia in adults. A review of pulmonary manifestations, risk factors and treatment. Respiration. 1992;59(6):339–343. [PubMed] [Google Scholar]
  • Gold E. Serologic and virus-isolation studies of patients with varicella or herpes-zoster infection. N Engl J Med. 1966 Jan 27;274(4):181–185. [PubMed] [Google Scholar]
  • Goodpasture EW, Anderson K. Infection of Human Skin, Grafted on the Chorioallantois of Chick Embryos, with the Virus of Herpes Zoster. Am J Pathol. 1944 May;20(3):447–455.[PMC free article] [PubMed] [Google Scholar]
  • Gray F, Bélec L, Lescs MC, Chrétien F, Ciardi A, Hassine D, Flament-Saillour M, de Truchis P, Clair B, Scaravilli F. Varicella-zoster virus infection of the central nervous system in the acquired immune deficiency syndrome. Brain. 1994 Oct;117(Pt 5):987–999. [PubMed] [Google Scholar]
  • Gray WL, Pumphrey CY, Ruyechan WT, Fletcher TM. The simian varicella virus and varicella zoster virus genomes are similar in size and structure. Virology. 1992 Feb;186(2):562–572. [PubMed] [Google Scholar]
  • Grose C. Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics. 1981 Nov;68(5):735–737. [PubMed] [Google Scholar]
  • Grose C. Glycoproteins of varicella-zoster virus and their herpes simplex virus homologs. Rev Infect Dis. 1991 Nov-Dec;13 (Suppl 11):S960–S963. [PubMed] [Google Scholar]
  • Grose C, Ng TI. Intracellular synthesis of varicella-zoster virus. J Infect Dis. 1992 Aug;166 (Suppl 1):S7–12. [PubMed] [Google Scholar]
  • Grossman MC, Grossman ME. Chronic hyperkeratotic herpes zoster and human immunodeficiency virus infection. J Am Acad Dermatol. 1993 Feb;28(2 Pt 2):306–308. [PubMed] [Google Scholar]
  • Guess HA, Broughton DD, Melton LJ, 3rd, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics. 1985 Oct;76(4):512–517. [PubMed] [Google Scholar]
  • Guess HA, Broughton DD, Melton LJ, 3rd, Kurland LT. Population-based studies of varicella complications. Pediatrics. 1986 Oct;78(4 Pt 2):723–727. [PubMed] [Google Scholar]
  • Gustafson TL, Lavely GB, Brawner ER, Jr, Hutcheson RH, Jr, Wright PF, Schaffner W. An outbreak of airborne nosocomial varicella. Pediatrics. 1982 Oct;70(4):550–556. [PubMed] [Google Scholar]
  • Haake DA, Zakowski PC, Haake DL, Bryson YJ. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis. 1990 Sep-Oct;12(5):788–798. [PubMed] [Google Scholar]
  • Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol. 1994 Jul 15;140(2):81–104. [PubMed] [Google Scholar]
  • Hammerschlag MR, Gershon AA, Steinberg SP, Clarke L, Gelb LD. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J Infect Dis. 1989 Sep;160(3):535–537. [PubMed] [Google Scholar]
  • Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant. 1994 Mar;13(3):277–283. [PubMed] [Google Scholar]
  • Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med. 1991 Nov 28;325(22):1545–1550. [PubMed] [Google Scholar]
  • Hayward A, Levin M, Wolf W, Angelova G, Gilden D. Varicella-zoster virus-specific immunity after herpes zoster. J Infect Dis. 1991 Apr;163(4):873–875. [PubMed] [Google Scholar]
  • Hayward AR. T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV. J Virol. 1990 Feb;64(2):651–655.[PMC free article] [PubMed] [Google Scholar]
  • Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol. 1987 Mar;7(2):174–178. [PubMed] [Google Scholar]
  • Hayward AR, Pontesilli O, Herberger M, Laszlo M, Levin M. Specific lysis of varicella zoster virus-infected B lymphoblasts by human T cells. J Virol. 1986 Apr;58(1):179–184.[PMC free article] [PubMed] [Google Scholar]
  • Heineman TC, Cohen JI. Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro. J Virol. 1994 May;68(5):3317–3323.[PMC free article] [PubMed] [Google Scholar]
  • Hellinger WC, Bolling JP, Smith TF, Campbell RJ. Varicella-zoster virus retinitis in a patient with AIDS-related complex: case report and brief review of the acute retinal necrosis syndrome. Clin Infect Dis. 1993 Feb;16(2):208–212. [PubMed] [Google Scholar]
  • Hickling JK, Borysiewicz LK, Sissons JG. Varicella-zoster virus-specific cytotoxic T lymphocytes (Tc): detection and frequency analysis of HLA class I-restricted Tc in human peripheral blood. J Virol. 1987 Nov;61(11):3463–3469.[PMC free article] [PubMed] [Google Scholar]
  • Hilt DC, Buchholz D, Krumholz A, Weiss H, Wolinsky JS. Herpes zoster ophthalmicus and delayed contralateral hemiparesis caused by cerebral angiitis: diagnosis and management approaches. Ann Neurol. 1983 Nov;14(5):543–553. [PubMed] [Google Scholar]
  • Hogan EL, Krigman MR. Herpes zoster myelitis. Evidence for viral invasion of spinal cord. Arch Neurol. 1973 Nov;29(5):309–313. [PubMed] [Google Scholar]
  • HOPE-SIMPSON RE. THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. Proc R Soc Med. 1965 Jan;58:9–20.[PMC free article] [PubMed] [Google Scholar]
  • Huang YC, Lin TY, Chiu CH. Acyclovir prophylaxis of varicella after household exposure. Pediatr Infect Dis J. 1995 Feb;14(2):152–154. [PubMed] [Google Scholar]
  • Huff JC, Bean B, Balfour HH, Jr, Laskin OL, Connor JD, Corey L, Bryson YJ, McGuirt P. Therapy of herpes zoster with oral acyclovir. Am J Med. 1988 Aug 29;85(2A):84–89. [PubMed] [Google Scholar]
  • Huff JC, Drucker JL, Clemmer A, Laskin OL, Connor JD, Bryson YJ, Balfour HH., Jr Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol. 1993;Suppl 1:93–96. [PubMed] [Google Scholar]
  • Hughes P, LaRussa P, Pearce JM, Lepow M, Steinberg S, Gershon A. Transmission of varicella-zoster virus from a vaccinee with leukemia, demonstrated by polymerase chain reaction. J Pediatr. 1994 Jun;124(6):932–935. [PubMed] [Google Scholar]
  • Hurley JK, Greenslade T, Lewy PR, Ahmadian Y, Firlit C. Varicella-zoster infections in pediatric renal transplant recipients. Arch Surg. 1980 Jun;115(6):751–752. [PubMed] [Google Scholar]
  • Hurwitz ES, Goodman RA. A cluster of cases of Reye syndrome associated with chickenpox. Pediatrics. 1982 Dec;70(6):901–906. [PubMed] [Google Scholar]
  • Ihara T, Kamiya H, Torigoe S, Sakurai M, Takahashi M. Viremic phase in a leukemic child after live varicella vaccination. Pediatrics. 1992 Jan;89(1):147–149. [PubMed] [Google Scholar]
  • Ilobi CP, Martin BA. A simple and sensitive assay for varicella-zoster virus. J Virol Methods. 1989 Feb;23(2):137–148. [PubMed] [Google Scholar]
  • Jacobson MA, Berger TG, Fikrig S, Becherer P, Moohr JW, Stanat SC, Biron KK. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990 Feb 1;112(3):187–191. [PubMed] [Google Scholar]
  • Jackson MA, Burry VF, Olson LC. Complications of varicella requiring hospitalization in previously healthy children. Pediatr Infect Dis J. 1992 Jun;11(6):441–445. [PubMed] [Google Scholar]
  • Jemsek J, Greenberg SB, Taber L, Harvey D, Gershon A, Couch RB. Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine (Baltimore) 1983 Mar;62(2):81–97. [PubMed] [Google Scholar]
  • Johnson C, Rome LP, Stancin T, Kumar ML. Humoral immunity and clinical reinfections following varicella vaccine in healthy children. Pediatrics. 1989 Sep;84(3):418–421. [PubMed] [Google Scholar]
  • Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML. Live attenuated varicella vaccine in healthy 12- to 24-month-old children. Pediatrics. 1988 Apr;81(4):512–518. [PubMed] [Google Scholar]
  • Johnson R, Milbourn PE. Central nervous system manifestations of chickenpox. Can Med Assoc J. 1970 Apr 25;102(8):831–834.[PMC free article] [PubMed] [Google Scholar]
  • Jura E, Chadwick EG, Josephs SH, Steinberg SP, Yogev R, Gershon AA, Krasinski KM, Borkowsky W. Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J. 1989 Sep;8(9):586–590. [PubMed] [Google Scholar]
  • Kangro HO, Ward A, Argent S, Heath RB, Cradock-Watson JE, Ridehalgh MK. Detection of specific IgM in varicella and herpes zoster by antibody-capture radioimmunoassay. Epidemiol Infect. 1988 Aug;101(1):187–195.[PMC free article] [PubMed] [Google Scholar]
  • KAPSENBERG JG. POSSIBLE ANTIGENIC RELATIONSHIP BETWEEN VARICELLA ZOSTER VIRUS AND HERPES SIMPLEX VIRUS. Arch Gesamte Virusforsch. 1964 Sep 9;15:67–73. [PubMed] [Google Scholar]
  • Karbassi M, Raizman MB, Schuman JS. Herpes zoster ophthalmicus. Surv Ophthalmol. 1992 May-Jun;36(6):395–410. [PubMed] [Google Scholar]
  • Kelley R, Mancao M, Lee F, Sawyer M, Nahmias A, Nesheim S. Varicella in children with perinatally acquired human immunodeficiency virus infection. J Pediatr. 1994 Feb;124(2):271–273. [PubMed] [Google Scholar]
  • Kinchington PR, Hougland JK, Arvin AM, Ruyechan WT, Hay J. The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J Virol. 1992 Jan;66(1):359–366.[PMC free article] [PubMed] [Google Scholar]
  • Kinchington PR, Ling P, Pensiero M, Moss B, Ruyechan WT, Hay J. The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). J Virol. 1990 Sep;64(9):4540–4548.[PMC free article] [PubMed] [Google Scholar]
  • Kinchington PR, Vergnes JP, Defechereux P, Piette J, Turse SE. Transcriptional mapping of the varicella-zoster virus regulatory genes encoding open reading frames 4 and 63. J Virol. 1994 Jun;68(6):3570–3581.[PMC free article] [PubMed] [Google Scholar]
  • Koropchak CM, Graham G, Palmer J, Winsberg M, Ting SF, Wallace M, Prober CG, Arvin AM. Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J Infect Dis. 1991 May;163(5):1016–1022. [PubMed] [Google Scholar]
  • Koropchak CM, Solem SM, Diaz PS, Arvin AM. Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J Virol. 1989 May;63(5):2392–2395.[PMC free article] [PubMed] [Google Scholar]
  • KRUGMAN S, GOODRICH CH, WARD R. Primary varicella pneumonia. N Engl J Med. 1957 Oct 31;257(18):843–848. [PubMed] [Google Scholar]
  • Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, Provost PJ, Watson BA, Starr SE, Plotkin SA. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine. 1991 Sep;9(9):643–647. [PubMed] [Google Scholar]
  • Kyong CU, Smith CD, Othersen HB. Necrotizing fasciitis of the abdominal wall as a complication of chickenpox. Pediatr Infect Dis. 1985 Jul-Aug;4(4):420–421. [PubMed] [Google Scholar]
  • Landry ML, Cohen SD, Mayo DR, Fong CK, Andiman WA. Comparison of fluorescent-antibody-to-membrane-antigen test, indirect immunofluorescence assay, and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus. J Clin Microbiol. 1987 May;25(5):832–835.[PMC free article] [PubMed] [Google Scholar]
  • Landry ML, Ferguson D. Comparison of latex agglutination test with enzyme-linked immunosorbent assay for detection of antibody to varicella-zoster virus. J Clin Microbiol. 1993 Nov;31(11):3031–3033.[PMC free article] [PubMed] [Google Scholar]
  • LaRussa P, Lungu O, Hardy I, Gershon A, Steinberg SP, Silverstein S. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol. 1992 Feb;66(2):1016–1020.[PMC free article] [PubMed] [Google Scholar]
  • Lawrence R, Gershon AA, Holzman R, Steinberg SP. The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med. 1988 Mar 3;318(9):543–548. [PubMed] [Google Scholar]
  • LeBoit PE, Límová M, Yen TS, Palefsky JM, White CR, Jr, Berger TG. Chronic verrucous varicella-zoster virus infection in patients with the acquired immunodeficiency syndrome (AIDS). Histologic and molecular biologic findings. Am J Dermatopathol. 1992 Feb;14(1):1–7. [PubMed] [Google Scholar]
  • Leclair JM, Zaia JA, Levin MJ, Congdon RG, Goldmann DA. Airborne transmission of chickenpox in a hospital. N Engl J Med. 1980 Feb 21;302(8):450–453. [PubMed] [Google Scholar]
  • Lécuru F, Taurelle R, Bernard JP, Parrat S, Lafay-pillet MC, Rozenberg F, Lebon P, Dommergues M. Varicella zoster virus infection during pregnancy: the limits of prenatal diagnosis. Eur J Obstet Gynecol Reprod Biol. 1994 Jul;56(1):67–68. [PubMed] [Google Scholar]
  • Leibovitz E, Kaul A, Rigaud M, Bebenroth D, Krasinski K, Borkowsky W. Chronic varicella zoster in a child infected with human immunodeficiency virus: case report and review of the literature. Cutis. 1992 Jan;49(1):27–31. [PubMed] [Google Scholar]
  • Levin MJ, Leventhal S, Masters HA. Factors influencing quantitative isolation of varicella-zoster virus. J Clin Microbiol. 1984 Jun;19(6):880–883.[PMC free article] [PubMed] [Google Scholar]
  • Levin MJ, Murray M, Zerbe GO, White CJ, Hayward AR. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis. 1994 Sep;170(3):522–526. [PubMed] [Google Scholar]
  • Liesegang TJ. Diagnosis and therapy of herpes zoster ophthalmicus. Ophthalmology. 1991 Aug;98(8):1216–1229. [PubMed] [Google Scholar]
  • Lieu TA, Cochi SL, Black SB, Halloran ME, Shinefield HR, Holmes SJ, Wharton M, Washington AE. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994 Feb 2;271(5):375–381. [PubMed] [Google Scholar]
  • Lieu TA, Finkler LJ, Sorel ME, Black SB, Shinefield HR. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents. Pediatrics. 1995 May;95(5):632–638. [PubMed] [Google Scholar]
  • Liu GT, Urion DK. Pre-eruptive varicella encephalitis and cerebellar ataxia. Pediatr Neurol. 1992 Jan-Feb;8(1):69–70. [PubMed] [Google Scholar]
  • Ljungman P, Lönnqvist B, Ringdén O, Skinhöj P, Gahrton G. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Nordic Bone Marrow Transplant Group. Bone Marrow Transplant. 1989 Nov;4(6):613–615. [PubMed] [Google Scholar]
  • Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985 Dec;152(6):1172–1181. [PubMed] [Google Scholar]
  • Lowe RS, Keller PM, Keech BJ, Davison AJ, Whang Y, Morgan AJ, Kieff E, Ellis RW. Varicella-zoster virus as a live vector for the expression of foreign genes. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3896–3900.[PMC free article] [PubMed] [Google Scholar]
  • Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics. 1992 Aug;90(2 Pt 1):216–220. [PubMed] [Google Scholar]
  • Machida H, Nishitani M. Drug susceptibilities of isolates of varicella-zoster virus in a clinical study of oral brovavir. Microbiol Immunol. 1990;34(4):407–411. [PubMed] [Google Scholar]
  • Mahalingam R, Wellish MC, Dueland AN, Cohrs RJ, Gilden DH. Localization of herpes simplex virus and varicella zoster virus DNA in human ganglia. Ann Neurol. 1992 Apr;31(4):444–448. [PubMed] [Google Scholar]
  • Mahalingam R, Wellish M, Lederer D, Forghani B, Cohrs R, Gilden D. Quantitation of latent varicella-zoster virus DNA in human trigeminal ganglia by polymerase chain reaction. J Virol. 1993 Apr;67(4):2381–2384.[PMC free article] [PubMed] [Google Scholar]
  • McGregor RS, Zitelli BJ, Urbach AH, Malatack JJ, Gartner JC., Jr Varicella in pediatric orthotopic liver transplant recipients. Pediatrics. 1989 Feb;83(2):256–261. [PubMed] [Google Scholar]
  • McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed) 1986 Dec 13;293(6561):1529–1532.[PMC free article] [PubMed] [Google Scholar]
  • Meier JL, Holman RP, Croen KD, Smialek JE, Straus SE. Varicella-zoster virus transcription in human trigeminal ganglia. Virology. 1993 Mar;193(1):193–200. [PubMed] [Google Scholar]
  • Meyers JD, Flournoy N, Thomas ED. Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant. J Infect Dis. 1980 Apr;141(4):479–487. [PubMed] [Google Scholar]
  • Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology. 1980 Jun;30(6):582–587. [PubMed] [Google Scholar]
  • Miller E, Cradock-Watson JE, Ridehalgh MK. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet. 1989 Aug 12;2(8659):371–373. [PubMed] [Google Scholar]
  • Moffat JF, Stein MD, Kaneshima H, Arvin AM. Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol. 1995 Sep;69(9):5236–5242.[PMC free article] [PubMed] [Google Scholar]
  • Moriuchi H, Moriuchi M, Smith HA, Cohen JI. Varicella-zoster virus open reading frame 4 protein is functionally distinct from and does not complement its herpes simplex virus type 1 homolog, ICP27. J Virol. 1994 Mar;68(3):1987–1992.[PMC free article] [PubMed] [Google Scholar]
  • Myers MG. Viremia caused by varicella-zoster virus: association with malignant progressive varicella. J Infect Dis. 1979 Aug;140(2):229–233. [PubMed] [Google Scholar]
  • Myers MG, Stanberry LR, Edmond BJ. Varicella-zoster virus infection of strain 2 guinea pigs. J Infect Dis. 1985 Jan;151(1):106–113. [PubMed] [Google Scholar]
  • Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis. 1995 Jan;171(1):13–17. [PubMed] [Google Scholar]
  • Nahass GT, Mandel MJ, Cook S, Fan W, Leonardi CL. Detection of herpes simplex and varicella-zoster infection from cutaneous lesions in different clinical stages with the polymerase chain reaction. J Am Acad Dermatol. 1995 May;32(5 Pt 1):730–733. [PubMed] [Google Scholar]
  • Ooi PL, Goh KT, Doraisingham S, Ling AE. Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health. 1992 Mar;23(1):22–25. [PubMed] [Google Scholar]
  • Ozaki T, Ichikawa T, Matsui Y, Kondo H, Nagai T, Asano Y, Yamanishi K, Takahashi M. Lymphocyte-associated viremia in varicella. J Med Virol. 1986 Jul;19(3):249–253. [PubMed] [Google Scholar]
  • Ozaki T, Kajita Y, Asano Y, Aono T, Yamanishi K. Detection of varicella-zoster virus DNA in blood of children with varicella. J Med Virol. 1994 Nov;44(3):263–265. [PubMed] [Google Scholar]
  • Ozaki T, Masuda S, Asano Y, Kondo K, Namazue J, Yamanishi K. Investigation of varicella-zoster virus DNA by the polymerase chain reaction in healthy children with varicella vaccination. J Med Virol. 1994 Jan;42(1):47–51. [PubMed] [Google Scholar]
  • Pahwa S, Biron K, Lim W, Swenson P, Kaplan MH, Sadick N, Pahwa R. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA. 1988 Nov 18;260(19):2879–2882. [PubMed] [Google Scholar]
  • Paryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med. 1986 Jun 12;314(24):1542–1546. [PubMed] [Google Scholar]
  • Pastuszak AL, Levy M, Schick B, Zuber C, Feldkamp M, Gladstone J, Bar-Levy F, Jackson E, Donnenfeld A, Meschino W, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med. 1994 Mar 31;330(13):901–905. [PubMed] [Google Scholar]
  • Patterson LE, Butler KM, Edwards MS. Clinical herpes zoster shortly following primary varicella in two HIV-infected children. Clin Pediatr (Phila) 1989 Aug;28(8):354–354. [PubMed] [Google Scholar]
  • Peck RW, Wootton R, Lee DR, Jackson SH, Posner J. The bioavailability and disposition of 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent. Br J Clin Pharmacol. 1995 Feb;39(2):143–149.[PMC free article] [PubMed] [Google Scholar]
  • Perera LP, Kaushal S, Kinchington PR, Mosca JD, Hayward GS, Straus SE. Varicella-zoster virus open reading frame 4 encodes a transcriptional activator that is functionally distinct from that of herpes simplex virus homology ICP27. J Virol. 1994 Apr;68(4):2468–2477.[PMC free article] [PubMed] [Google Scholar]
  • Perera LP, Mosca JD, Ruyechan WT, Hay J. Regulation of varicella-zoster virus gene expression in human T lymphocytes. J Virol. 1992 Sep;66(9):5298–5304.[PMC free article] [PubMed] [Google Scholar]
  • Pérez JL, García A, Niubò J, Salvà J, Podzamczer D, Martín R. Comparison of techniques and evaluation of three commercial monoclonal antibodies for laboratory diagnosis of varicella-zoster virus in mucocutaneous specimens. J Clin Microbiol. 1994 Jun;32(6):1610–1613.[PMC free article] [PubMed] [Google Scholar]
  • Perren TJ, Powles RL, Easton D, Stolle K, Selby PJ. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med. 1988 Aug 29;85(2A):99–101. [PubMed] [Google Scholar]
  • Peters AC, Versteeg J, Lindeman J, Bots GT. Varicella and acute cerebellar ataxia. Arch Neurol. 1978 Nov;35(11):769–771. [PubMed] [Google Scholar]
  • Plotkin SA, Starr SE, Connor K, Morton D. Zoster in normal children after varicella vaccine. J Infect Dis. 1989 May;159(5):1000–1001. [PubMed] [Google Scholar]
  • Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: clinical review and current management. Ann Neurol. 1986 Dec;20(6):651–664. [PubMed] [Google Scholar]
  • Poscher ME. Successful treatment of varicella zoster virus meningoencephalitis in patients with AIDS: report of four cases and review. AIDS. 1994 Aug;8(8):1115–1117. [PubMed] [Google Scholar]
  • Preblud SR. Age-specific risks of varicella complications. Pediatrics. 1981 Jul;68(1):14–17. [PubMed] [Google Scholar]
  • Preblud SR. Varicella: complications and costs. Pediatrics. 1986 Oct;78(4 Pt 2):728–735. [PubMed] [Google Scholar]
  • Preblud SR, Bregman DJ, Vernon LL. Deaths from varicella in infants. Pediatr Infect Dis. 1985 Sep-Oct;4(5):503–507. [PubMed] [Google Scholar]
  • Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis. 1984 Nov-Dec;3(6):505–509. [PubMed] [Google Scholar]
  • Prober CG, Gershon AA, Grose C, McCracken GH, Jr, Nelson JD. Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J. 1990 Dec;9(12):865–869. [PubMed] [Google Scholar]
  • Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children--a collaborative study. J Pediatr. 1982 Oct;101(4):622–625. [PubMed] [Google Scholar]
  • Purifoy DJ, Beauchamp LM, de Miranda P, Ertl P, Lacey S, Roberts G, Rahim SG, Darby G, Krenitsky TA, Powell KL. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol. 1993;Suppl 1:139–145. [PubMed] [Google Scholar]
  • Ragozzino MW, Melton LJ, 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982 Sep;61(5):310–316. [PubMed] [Google Scholar]
  • Ragozzino MW, Melton LJ, 3rd, Kurland LT, Chu CP, Perry HO. Risk of cancer after herpes zoster: a population-based study. N Engl J Med. 1982 Aug 12;307(7):393–397. [PubMed] [Google Scholar]
  • Rawlinson WD, Dwyer DE, Gibbons VL, Cunningham AL. Rapid diagnosis of varicella-zoster virus infection with a monoclonal antibody based direct immunofluorescence technique. J Virol Methods. 1989 Jan;23(1):13–18. [PubMed] [Google Scholar]
  • ROSS AH. Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med. 1962 Aug 23;267:369–376. [PubMed] [Google Scholar]
  • Sadzot-Delvaux C, Merville-Louis MP, Delrée P, Marc P, Piette J, Moonen G, Rentier B. An in vivo model of varicella-zoster virus latent infection of dorsal root ganglia. J Neurosci Res. 1990 May;26(1):83–89. [PubMed] [Google Scholar]
  • Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, Mills J, Biron KK. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991 Jul 1;115(1):19–21. [PubMed] [Google Scholar]
  • Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994 Oct;38(10):2454–2457.[PMC free article] [PubMed] [Google Scholar]
  • Sawyer MH, Chamberlin CJ, Wu YN, Aintablian N, Wallace MR. Detection of varicella-zoster virus DNA in air samples from hospital rooms. J Infect Dis. 1994 Jan;169(1):91–94. [PubMed] [Google Scholar]
  • Sawyer MH, Wu YN, Chamberlin CJ, Burgos C, Brodine SK, Bowler WA, LaRocco A, Oldfield EC, 3rd, Wallace MR. Detection of varicella-zoster virus DNA in the oropharynx and blood of patients with varicella. J Infect Dis. 1992 Oct;166(4):885–888. [PubMed] [Google Scholar]
  • Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD. Racial differences in the occurrence of herpes zoster. J Infect Dis. 1995 Mar;171(3):701–704. [PubMed] [Google Scholar]
  • Schmidbauer M, Budka H, Pilz P, Kurata T, Hondo R. Presence, distribution and spread of productive varicella zoster virus infection in nervous tissues. Brain. 1992 Apr;115(Pt 2):383–398. [PubMed] [Google Scholar]
  • Schmidt NJ, Gallo D, Devlin V, Woodie JD, Emmons RW. Direct immunofluorescence staining for detection of herpes simplex and varicella-zoster virus antigens in vesicular lesions and certain tissue specimens. J Clin Microbiol. 1980 Nov;12(5):651–655.[PMC free article] [PubMed] [Google Scholar]
  • Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood. 1989 Sep;74(4):1424–1427. [PubMed] [Google Scholar]
  • Sharp M, Terada K, Wilson A, Nader S, Kinchington PE, Ruyechan WT, Hay J, Arvin AM. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis. 1992 May;165(5):852–858. [PubMed] [Google Scholar]
  • Shiraki K, Ochiai H, Matsui S, Aiba N, Yoshida Y, Okuno T, Yamanishi K, Takahashi M. Processing of hepatitis B virus surface antigen expressed by recombinant Oka varicella vaccine virus. J Gen Virol. 1992 Jun;73(Pt 6):1401–1407. [PubMed] [Google Scholar]
  • Siegel M, Fuerst HT, Peress NS. Comparative fetal mortality in maternal virus diseases. A prospective study on rubella, measles, mumps, chicken pox and hepatitis. N Engl J Med. 1966 Apr 7;274(14):768–771. [PubMed] [Google Scholar]
  • Spector T, Harrington JA, Morrison RW, Jr, Lambe CU, Nelson DJ, Averett DR, Biron K, Furman PA. 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir. Proc Natl Acad Sci U S A. 1989 Feb;86(3):1051–1055.[PMC free article] [PubMed] [Google Scholar]
  • Srugo I, Israele V, Wittek AE, Courville T, Vimal VM, Brunell PA. Clinical manifestations of varicella-zoster virus infections in human immunodeficiency virus-infected children. Am J Dis Child. 1993 Jul;147(7):742–745. [PubMed] [Google Scholar]
  • Starr SE. Varicella in children receiving steroids for asthma: risks and management. Pediatr Infect Dis J. 1992 May;11(5):419–420. [PubMed] [Google Scholar]
  • Steinberg SP, Gershon AA. Measurement of antibodies to varicella-zoster virus by using a latex agglutination test. J Clin Microbiol. 1991 Jul;29(7):1527–1529.[PMC free article] [PubMed] [Google Scholar]
  • Stevens DA, Merigan TC. Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial. Arch Intern Med. 1980 Jan;140(1):52–54. [PubMed] [Google Scholar]
  • Straus SE. Clinical and biological differences between recurrent herpes simplex virus and varicella-zoster virus infections. JAMA. 1989 Dec 22;262(24):3455–3458. [PubMed] [Google Scholar]
  • Meier JL, Straus SE. Comparative biology of latent varicella-zoster virus and herpes simplex virus infections. J Infect Dis. 1992 Aug;166 (Suppl 1):S13–S23. [PubMed] [Google Scholar]
  • Straus SE, Reinhold W, Smith HA, Ruyechan WT, Henderson DK, Blaese RM, Hay J. Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N Engl J Med. 1984 Nov 22;311(21):1362–1364. [PubMed] [Google Scholar]
  • Takahashi M. Current status and prospects of live varicella vaccine. Vaccine. 1992;10(14):1007–1014. [PubMed] [Google Scholar]
  • Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr. 1990 Feb;116(2):184–189. [PubMed] [Google Scholar]
  • Vafai A, Wellish M, Gilden DH. Expression of varicella-zoster virus in blood mononuclear cells of patients with postherpetic neuralgia. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2767–2770.[PMC free article] [PubMed] [Google Scholar]
  • Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother. 1989 Oct;33(10):1765–1773.[PMC free article] [PubMed] [Google Scholar]
  • Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC., 3rd Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med. 1992 Sep 1;117(5):358–363. [PubMed] [Google Scholar]
  • Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, Cnaan A, Starr SE. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis. 1995 Feb;20(2):316–319. [PubMed] [Google Scholar]
  • Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. J Infect Dis. 1994 Jan;169(1):197–199. [PubMed] [Google Scholar]
  • Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics. 1993 Jan;91(1):17–22. [PubMed] [Google Scholar]
  • Webster CB, Chen D, Horgan M, Olivo PD. The varicella-zoster virus origin-binding protein can substitute for the herpes simplex virus origin-binding protein in a transient origin-dependent DNA replication assay in insect cells. Virology. 1995 Jan 10;206(1):655–660. [PubMed] [Google Scholar]
  • Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med. 1984 May 31;310(22):1409–1415. [PubMed] [Google Scholar]
  • Weller TH. Varicella and herpes zoster: a perspective and overview. J Infect Dis. 1992 Aug;166 (Suppl 1):S1–S6. [PubMed] [Google Scholar]
  • White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, Provost PJ, Ellis RW, Gerety RJ, Calandra GB. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics. 1991 May;87(5):604–610. [PubMed] [Google Scholar]
  • Whitley RJ. Therapeutic approaches to varicella-zoster virus infections. J Infect Dis. 1992 Aug;166 (Suppl 1):S51–S57. [PubMed] [Google Scholar]
  • Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis. 1992 Jan;165(1):119–126. [PubMed] [Google Scholar]
  • Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994 Mar 31;330(13):896–900. [PubMed] [Google Scholar]
  • Wood MJ, McKendrick MW, McGill JI. Oral acyclovir for acute herpes zoster infections in immune-competent adults. Infection. 1987;15 (Suppl 1):S9–13. [PubMed] [Google Scholar]
  • Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med. 1988 Aug 29;85(2A):79–83. [PubMed] [Google Scholar]
  • Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, LeGore J. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis. 1983 Apr;147(4):737–743. [PubMed] [Google Scholar]
  • Zhang Y, Cosyns M, Levin MJ, Hayward AR. Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Immunol. 1994 Oct;98(1):128–133.[PMC free article] [PubMed] [Google Scholar]
  • Zhu Z, Gershon MD, Ambron R, Gabel C, Gershon AA. Infection of cells by varicella zoster virus: inhibition of viral entry by mannose 6-phosphate and heparin. Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3546–3550.[PMC free article] [PubMed] [Google Scholar]
Department of Pediatrics, Stanford University School of Medicine, California 94305-5119, USA. MN.AMA@FORSYTHE.STANFORD.EDU
Department of Pediatrics, Stanford University School of Medicine, California 94305-5119, USA. MN.AMA@FORSYTHE.STANFORD.EDU
Copyright notice

Abstract

Varicella-zoster virus (VZV) is a ubiquitous human alphaherpesvirus that causes varicella (chicken pox) and herpes zoster (shingles). Varicella is a common childhood illness, characterized by fever, viremia, and scattered vesicular lesions of the skin. As is characteristic of the alphaherpesviruses, VZV establishes latency in cells of the dorsal root ganglia. Herpes zoster, caused by VZV reactivation, is a localized, painful, vesicular rash involving one or adjacent dermatomes. The incidence of herpes zoster increases with age or immunosuppression. The VZV virion consists of a nucleocapsid surrounding a core that contains the linear, double-stranded DNA genome; a protein tegument separates the capsid from the lipid envelope, which incorporates the major viral glycoproteins. VZV is found in a worldwide geographic distribution but is more prevalent in temperate climates. Primary VZV infection elicits immunoglobulin G (IgG), IgM, and IgA antibodies, which bind to many classes of viral proteins. Virus-specific cellular immunity is critical for controlling viral replication in healthy and immunocompromised patients with primary or recurrent VZV infections. Rapid laboratory confirmation of the diagnosis of varicella or herpes zoster, which can be accomplished by detecting viral proteins or DNA, is important to determine the need for antiviral therapy. Acyclovir is licensed for treatment of varicella and herpes zoster, and acyclovir, valacyclovir, and famciclovir are approved for herpes zoster. Passive antibody prophylaxis with varicella-zoster immune globulin is indicated for susceptible high-risk patients exposed to varicella. A live attenuated varicella vaccine (Oka/Merck strain) is now recommended for routine childhood immunization.

Abstract
Full Text
Selected References
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.